News

Filter

Current filters:

None

7877 to 7886 of 95916 results

Spectrum in-licenses novel GCSF drug from Hanmi Pharma

01-02-2012

USA-based Spectrum Pharmaceuticals (NasdaqGS: SPPI) has entered into a co-development and commercialization…

Hanmi PharmaceuticalLicensingOncologyPharmaceuticalSpectrum Pharmaceuticals

Impax buys US rights to Zomig

01-02-2012

Impax Pharmaceuticals, the branded products business unit of Impax Laboratories (Nasdaq: IPXL) has licensed…

AstraZenecaImpax LaboratoriesLicensingMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalZomig

Janssen drops deal with Orexo for OX-CLI/OX-ESI

01-02-2012

US health care major Johnson & Johnson INYSE: JNJ) subsidiary Janssen has decided to end research collaboration…

FinancialJanssenJohnson & JohnsonLicensingOrexo ABPharmaceuticalRespiratory and Pulmonary

Global osteoporosis market report sees strong showing in China

01-02-2012

The global market for drugs to treat osteoporosis was estimated to be worth $7.3 billion in 2010 and…

AmgenAnti-Arthritics/RheumaticsAsia-PacificGlobalMarkets & MarketingPharmaceuticalXgeva

FDA approves combo diabetes drug Jentadueto and Kalydeco

01-02-2012

The US Food and Drug Administration) has approved Jentadueto (linagliptin/metformin hydrochloride) tablets,…

Boehringer IngelheimDiabetesEli LillyJentaduetoKalydecolinagliptinNorth AmericaPharmaceuticalRare diseasesRegulationVertex

Pfizer’s fourth-quarter net income slumps 50%

01-02-2012

Global drug behemoth Pfizer (NYSE: PFE) reported fourth-quarter 2011 net income of $1.4 billion, a year-on-year…

FinancialPfizerPharmaceutical

Roche posts strong 2011 profits, upbeat on 2012

01-02-2012

Swiss drug major Roche (ROG: SIX) this morning announced that group sales for the full-year 2011 grew…

FinancialPharmaceuticalRoche

Eli Lilly results hammered by Zyprexa patent loss

01-02-2012

US drug major Eli Lilly (NYSE: LLY) said that fourth-quarter 2011 global sales dropped 2% to $6.05 billion.…

Eli LillyFinancialPharmaceutical

Solid 2011 financials from Biogen Idec but forecast disappoints

01-02-2012

US biotech firm Biogen Idec (Nasdaq: BIIB) announced its full year and fourth quarter 2011 results which…

Biogen IdecBiotechnologyFinancial

7877 to 7886 of 95916 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top